Home

Neurocrine Biosciences, Inc. - Common Stock (NBIX)

118.81
-0.00 (-0.00%)

Neurocrine Biosciences is a biopharmaceutical company focused on developing innovative treatments for neurological and endocrine diseases

The company conducts research and creates drug therapies aimed at addressing the unmet medical needs of patients suffering from conditions such as movement disorders, psychiatric disorders, and hormonal disorders. Through a combination of scientific expertise and cutting-edge technology, Neurocrine strives to enhance patient outcomes and improve quality of life, while expanding its pipeline of therapeutic options in the field of neuroscience and endocrinology.

SummaryNewsPress ReleasesChartHistoricalFAQ
Why Neurocrine Biosciences Stock Sank Todayfool.com
Via The Motley Fool · February 10, 2025
Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?benzinga.com
Skyworks Solutions, Estee Lauder, Venture Global, Neurocrine Biosciences, Moderna, Illumina, IDEX Corporation, PTC Inc, PayPal Holdings, Skechers U.S.A. and Avantor were worst performers, fell up to 25%.
Via Benzinga · February 9, 2025
Neurocrine Biosciences Reports Mixed Q4fool.com
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.
Via The Motley Fool · February 7, 2025
Why the quality investor may take a look at NASDAQ:NBIX.chartmill.com
A fundamental analysis of (NASDAQNBIX): Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC NASDAQ:NBIXNASDAQNBIX)
Via Chartmill · February 7, 2025
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?benzinga.com
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth despite near-term challenges.
Via Benzinga · February 7, 2025
Earnings Summary: Neurocrine Biosciences Q4benzinga.com
Via Benzinga · February 6, 2025
Earnings Scheduled For February 6, 2025benzinga.com
Via Benzinga · February 6, 2025
Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)benzinga.com
Via Benzinga · February 4, 2025
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.chartmill.com
NEUROCRINE BIOSCIENCES INC (NASDAQNBIX) qualifies as a high growth stock and is consolidating.
Via Chartmill · January 7, 2025
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · February 7, 2025
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Druginvestors.com
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Via Investor's Business Daily · February 6, 2025
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.chartmill.com
Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Via Chartmill · February 5, 2025
NASDAQ:NBIX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.chartmill.com
NEUROCRINE BIOSCIENCES INC may be an undervalued stock option. NASDAQ:NBIX retains a strong financial foundation and an attractive price tag.
Via Chartmill · January 30, 2025
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rightsbenzinga.com
Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.
Via Benzinga · January 28, 2025
NASDAQ:NBIX: good value for what you're paying.chartmill.com
Investors should take notice ofNEUROCRINE BIOSCIENCES INC (NASDAQNBIX)—it offers a great deal for the fundamentals it presents.
Via Chartmill · January 3, 2025
What Analysts Are Saying About Neurocrine Biosciences Stockbenzinga.com
Via Benzinga · December 20, 2024
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.chartmill.com
Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQNBIX).
Via Chartmill · January 15, 2025
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Deserves Consideration as a Quality Investment.chartmill.com
NEUROCRINE BIOSCIENCES INC (NASDAQNBIX) Exhibits Quality Stock Traits. Here's Why.
Via Chartmill · January 13, 2025
Neurocrine Biosciences Stock Sees RS Rating Upgradeinvestors.com
Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71.
Via Investor's Business Daily · December 24, 2024
While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable.chartmill.com
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Via Chartmill · December 24, 2024
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?benzinga.com
The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio?
Via Benzinga · December 22, 2024
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potentialbenzinga.com
Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation.
Via Benzinga · December 16, 2024
Neurocrine Wins FDA Approval For Genetic Disorder Druginvestors.com
The company can launch within a week, says Chief Executive Kyle Gano.
Via Investor's Business Daily · December 13, 2024
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.chartmill.com
NEUROCRINE BIOSCIENCES INC (NASDAQNBIX) stands out as a growth opportunity that won't break the bank.
Via Chartmill · December 3, 2024
Screening For Black Friday Bargains In The Stock Marketbenzinga.com
Via Benzinga · December 3, 2024